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HES solutions in critical 
illness, trauma and 
perioperative period
ABSTRACT
In the last few years, many studies and meta-analyses have demonstrated that hydroxyethyl starch (HES) solutions increase 
the risk of acute renal failure and mortality in critically ill patients. Some studies suggest complete avoidance of HES solu-
tions in patients of all categories. On the other hand, recent studies and analyses suggest that HES solutions may be used 
in hypovolemic critically ill patients and in the perioperative setting. The main problem in everyday clinical practice and in 
a rational fluid management approach is that treatment with alternatives to HES solutions is not always pathophysiologically 
justified (crystalloids) or confirmed in randomised controlled trials (gelatins, albumins). 
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Introduction 
The synthesis of hydroxyethyl starch 
(HES) solutions of the third generation 
should have relieved anxiety concerning 
the adverse effects of older generations 
of HES solutions, in particular coagula-
tion disorders, renal injuries and allergic 
reactions. (1) However, in the past few 
years many studies and meta-analyses 
have demonstrated that HES solutions, 
regardless of their basic properties, 
increase the risk of acute renal failure 
(ARF) and mortality in critically ill pati-
ents. Based on these findings, recom-
mendations have recently appeared in 
literature suggesting that HES solutions 
should be avoided in cases of critical 
illness and in the perioperative setting. 
The “Surviving Sepsis Campaign” gui-
delines (SSCG) from 2012 support a 
high recommendation grade against 
the use of HES solutions and suggest 
that crystalloid solutions should be used 
in the resuscitation of severe sepsis and 
septic shock. The SSCG suggest the 
use of albumin when patients require 
substantial amounts of crystalloids. (2) 
At the end of 2012, the European Medici-
nes Agency (EMA) evaluated the safety, 
benefits and risks of solutions which 
contain HES. In June 2013, the EMA’s 
Pharmacovigilance Risk Assessment 
Committee (PRAC) suggested that the 
benefits of HES solutions no longer 
exceed their risks and that HES soluti-
ons should be suspended in all patient 
populations. After an additional analysis, 
PRAC agreed that HES solution could 
continue to be used in some populations 
such as hypovolemic patients with acute 
blood loss when treatment with alterna-
tive solutions such as crystalloids is not 
considered to be sufficient. (3)
HES solutions in severe 
sepsis and septic shock
The German multicentre, prospective, 
randomised study (VISEP) investigated 
the effects of intensive and conventio-
nal insulin therapy, of 10% HES 200/05 
solution and of modified Ringer’s lactate 
in patients with severe sepsis. (4) The 
study was terminated early for safety 
reasons concerning an elevated rate 
of severe hypoglycaemia in patients on 
intensive insulin therapy and higher rates 
of ARF and RRT associated with the 
HES solution therapy. Patients in the 
HES group had a lower median platelet 
count and received more units of pac-
ked red cells. The mortality rate within 
28 days was similar in both groups. A 
trend toward higher 90-day mortality 
rate was observed in the HES group. 
The main limitation of the study was 
that the older hyperoncotic HES soluti-
on was administered without a proper 
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determination of the patients’ volume 
status. The baseline patients’ characte-
ristics at the time of randomisation sug-
gested that they were not hypovolemic. 
High volumes of HES solutions were 
administered at the beginning of ran-
domisation, when the kidneys are more 
sensitive to oncotic load. (1) In the Fren-
ch multicentre, prospective, controlled, 
randomised and double-blinded study 
(CRYSTMAS) on 174 patients with seve-
re sepsis, hemodynamic effects and a 
safety evaluation of 6% HES 130/04 and 
0.9% NaCl solutions were compared. 
(5) Results of the study demonstrated 
that hemodynamic stability could be 
achieved using lower volumes of HES 
solutions in a shorter time period. Dif-
ferences between groups in the Acute 
Kidney Injury Network classification and 
the Risk, Injury, Failure, Loss, End-Stage 
Kidney Disease criteria were not found. 
There were no differences in the coagu-
lation parameters or in the 90-day morta-
lity rate. A notable criticism of the SSCG 
is that the CRYSTMAS study was under-
powered and that there was a 6% higher 
mortality in the HES group that was not 
referred to as statistically important. In 
the Scandinavian multicentre, randomi-
sed, parallel-group and double-blinded 
study (6 S) carried out on 798 patients 
with severe sepsis, the effects of the 
balanced HES 130/0.42 solution con-
cerning the mortality rate or end-stage 
kidney failure were compared to those 
of a balanced crystalloid solution. (6) 
The study design enabled a proper eva-
luation of the molecular effects of HES 
because Ringer’s acetate was a carrier 
for HES and a comparable crystalloid 
solution. The volume of administered 
solutions was similar in both groups, as 
were the hemodynamic parameters. The 
90-day mortality rate was significantly 
higher in the HES group. More patients 
in the HES group were treated with the 
RRT, had severe bleeding and received 
blood products. The main limitation of the 
study was that patients in both groups 
were not hypovolemic at the time of the 
randomisation. Volume management in 
both groups was guided by clinical end-
points, without objective hemodyna-
mic monitoring. The design of the study 
enabled clinicians to administer high 
amounts of the investigated solutions 
without knowing their basic properties. 
It is a questionable approach in terms 
of rational volume management. Pati-
ents with ARF were randomised in both 
groups and precise indications for the 
RRT were not established in the study 
protocol. In the prospective, multicentre, 
randomised, parallel group, controlled 
and blind study (CHEST) conducted in 
32 hospitals in Australia and New Zea-
land on 7,000 patients, the effects of 
HES solutions or saline were compared 
concerning 90-day mortality, ARF and 
RRT, as well as concerning new organ 
failures for cardiovascular, respiratory, 
coagulation and liver systems. (7) The 
results of the study demonstrated similar 
28-day and 90-day mortality in both gro-
ups. A larger proportion of patients who 
where resuscitated with HES solutions 
were treated with RRT. HES treatment 
was associated with lower volumes of 
resuscitation fluid and increased the use 
of blood products. There was no signifi-
cant difference in rates of new respira-
tory or coagulation organ failure. A lower 
incidence of new cardiovascular organ 
failure along with less frequent use of 
vasopressors, and a higher incidence of 
new hepatic organ failure were noticed 
in the HES group. HES was associated 
with significantly more adverse events, 
mostly pruritus and rush. There are few 
limitations of the study. Patients were 
randomised 11 hours after they were 
admitted to the ICU and at the time of 
the randomisation they were not hypo-
volemic. The study solutions were admi-
nistered without objective hemodynamic 
monitoring. Similarly to the 6 S study, 
rational volume administration was pre-
vented by the fact that clinicians did not 
know the basic properties of solutions 
they administered. Although the clinici-
ans were unaware of study-group assi-
gnments, the lack of precise indications 
for RRT might affect the study results.
HES solutions in critically 
ill, surgical and trauma 
patients 
Gattas et al. performed a meta-analysis 
of 35 randomised and controlled studi-
es with 10,391 patients. (8) The main 
goals of the analysis were to investigate 
effects of 6% HES solutions (130/0.4 
and 130/0.42) on mortality and RRT 
in acute illness. The authors conclu-
ded that fluid resuscitation of acutely ill 
adults with 6% HES 130 is associated 
with an increased risk of death and 
treatment with RRT. 
Zarychanski et al. performed a meta-
analysis of 38 studies and 10,880 cri-
tically ill patients and compared HES 
solutions with crystalloid, albumin and 
gelatine solutions. (9) The results of the 
analysis demonstrated a higher mortali-
ty rate, ARF and RRT frequency associ-
ated with the administration of HES. 
In the Perel et al. review, the effects 
of colloid and crystalloid solutions in 
the volume management of critically 
ill patients were analysed. (10) The 
authors concluded that there is no 
evidence from randomised controlled 
trials that colloids reduce the risk of 
death in patients with trauma, burns or 
following surgery and that use of HES 
solutions might even increase mortality. 
As colloids are more expensive than 
crystalloids their use in clinical practice 
is unjustified. 
The main goals of the Mutter et al. meta-
analysis were to compare the effects 
of HES and other solutions in various 
patient categories. (11) The analysis 
included 42 studies with 11,399 pati-
ents. The results of the analysis showed 
that HES solutions, irrespective of their 
molecular weight (MW), degree of sub-
stitution (DS) or substitution pattern, 
increase the risk of ARF and RRT in all 
patient categories. 
In another systematic review, with meta-
analyses of randomised clinical trials on 
patients with sepsis, Haase et al. asse-
ssed the effects of fluid therapy with 
HES 130/0.38-0.45 solutions versus 
crystalloid or albumin solutions on mor-
tality, kidney injury, bleeding and serio-
us adverse events. The authors conclu-
ded that HES 130/0.38-0.45 increased 
the use of RRT and transfusion with red 
blood cells and increased the frequen-
cy of serious adverse events. (12) 
The multicentre, prospective, rando-
mised and open label trial (CRISTAL) 
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was conducted in 57 ICUs in France, 
Belgium, North Africa and Canada and 
included 2,857 patients with hypovole-
mic shock due to sepsis, trauma and 
other causes. (13) The main goals of 
the study were to compare the effects 
of colloid and crystalloid solutions on 
28-day and 90-day mortality in patients 
with hypovolemic shock and days alive 
and not receiving RRT, mechanical ven-
tilation or vasopressor therapy. In the 
crystalloids group, about 86% of patients 
were resuscitated with isotonic saline 
and about 17% with buffered solutions. 
In the colloids group, about 70% of pati-
ents received HES and about 35% rece-
ived gelatins. Patients in the crystalloids 
group received higher volumes of fluids 
to accomplish the same hemodynamic 
goals as patients in the colloids group. 
A difference in the 28-day mortality rate 
was not found. Within 90 days, the mor-
tality rate was lower in the colloids group. 
There were no differences in the number 
of patients treated with the RRT. Patients 
in the colloids group had more days 
alive without mechanical ventilation and 
vasopressor therapy. Unlike other simi-
lar studies, the CRISTAL study included 
only hypovolemic patients. The different 
hemodynamic parameters at the start 
of the randomisation and the lower total 
dose of administered starches might 
have positively affected the mortality and 
RRT risks in this trial. In addition, patients 
with severe chronic renal failure were not 
included in the study. The reduced car-
diovascular and respiratory failure in the 
colloids group may have contributed to 
renal protection. The possible limitations 
of the study include the administration 
of open-labelled fluids, a recruitment 
period of nine years and protocol viola-
tions in both groups. The knowledge of 
allocation of the investigated solutions 
by physicians might have influenced the 
requirements of RRT. 
In the Martin et al. meta-analysis, which 
included 17 studies and 1,230 surgical 
patients, renal safety with the active 
substance of the latest generation of 
waxy maize-derived HES was evalu-
ated. The authors found no evidence 
of renal dysfunction caused by HES 
130/0.40. (14) 
In the Van Der Linden et al. analysis, 
which included 59 studies and 4,529 
patients, the safety of modern HES solu-
tions was evaluated during the periope-
rative period. (15) Tetrastarches did not 
induce adverse renal effects (39 trials; 
3,389 patients), increased blood loss 
(38 trials; 3280 patients), erythrocyte 
transfusion (20 trials; 2,151 patients) or 
mortality. The authors concluded that 
modern HES solutions did not induce 
any adverse effects intraoperatively or 
in the immediate postoperative period. 
The main limitation of the analysis was 
that the follow-up period was limited in 
the evaluated trials and possible long-
term adverse effects could not be esti-
mated. The authors argued that the 
main differences between their analysis 
and other similar studies and analyses 
concerned the population investiga-
ted and patients’ endovascular functi-
on. Critical and septic patients have 
damaged glycocalix and endovascular 
barrier that promote the extravasation 
of HES molecules into the extracellular 
compartment, the loss of intravascular 
colloid function and the administration 
of additional volumes of solutions. An 
increased amount of HES molecules 
in the extracellular compartment could 
be responsible for the increased late 
mortality and the frequency of ARF in 
critically ill and septic patients. (15) The 
presumable mechanisms may include 
intake of starch into epithelial cells of 
the proximal renal tubules and tubu-
lar obstruction associated with hyper-
viscose urine and inflammation of the 
renal interstitium. (16) A lower volume 
of HES solutions administered during 
the first 48 hours was not associated 
with ARF or increased ICU mortality in 
an observational retrospective study on 
363 patients. (17) Beside the patients’ 
characteristics, different structures of 
HES solutions concerning MW, DS, ori-
gin of the starch, amylopectin percenta-
ge and C2/C6 substitution pattern may 
be responsible for different outcomes 
and adverse effects. 
In the Kozek-Langenecker et al. anal-
ysis, which included seven studies and 
449 major surgical patients, the impact 
of HES 130/04 solutions on coagulation 
parameters, blood loss and transfusion 
volumes was significantly decreased in 
comparison to HES 200/05 solutions. 
(18) Mechanisms associated with incre-
ased bleeding after the administration 
of HES solutions include hemodilution, 
thrombocyte dysfunction, actions on GP 
IIb-IIIa receptors, increased fibrinolytic 
reactivity, decreased levels of factor VIII 
and von Willebrand factor and fibrine 
polymerisation. (18,19) In healthy volun-
teers, the repeated administration of 
HES 130/0.42 showed no accumulation 
and fewer tendencies to time-dependent 
changes in pharmacokinetic parameters 
than HES 200/0.5. (20) 
The Bellmann et al. meta-analysis did 
not support the hypothesis that lower 
MW and DS decrease the tissue upta-
ke of HES. (21) In terms of colloid 
osmotic and hemodilution effects, HES 
130/0.42 showed an equivalency with 
HES 130/0.4 and had the fastest cle-
arance from the circulation. (22) The 
effects of both HES solutions on coa-
gulation were similar. In comparison to 
crystalloids, more severe hemostatic 
defects were noticed, mostly expressed 
as an impairment of fibrin polymerizati-
on. (23)
The administration of HES solutions in 
trauma was evaluated in a randomi-
sed, controlled, double-blinded study 
on 109 patients (FIRST). In patients 
with penetrating trauma, a significantly 
lower volume of HES solutions was 
administered in comparison to the 0.9% 
NaCl. In patients with blunt trauma, 
differences in volume administration 
were not found. Patients with blunt tra-
uma received significantly more eryt-
hrocyte concentrates, probably beca-
use of higher median Injury Severity 
Score (ISS). The administration of HES 
in patients with penetrating trauma was 
associated with a significantly lower 
serum lactate levels and decreased 
frequency of ARF. Hemodynamic para-
meters, return of the bowel function and 
mortality rate were comparable in both 
groups. (24) 
In a retrospective study on 1,867 pati-
ents with blunt trauma, an increased 
exposure to blood products was noti-
ced when HES 130/0.4 was admini-
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stered in comparison to 0.9% NaCl. 
The reason for such a finding might 
be due to more extensive microvascu-
lar injury caused by blunt trauma. (25) 
Nevertheless, the study results were not 
conclusive because patients in the HES 
group had higher ISS and worse initial 
coagulation parameters. The authors 
concluded that the incidence of coa-
gulopathy is associated with the seve-
rity of traumatic injury, not with volume 
management.
Alternatives to HES 
solutions
Although the SSCG suggest the use of 
crystalloids in severe sepsis and septic 
shock, it is questionable whether such 
an approach can be applicable to all 
critically ill and perioperative patients. 
From the pathophysiologic point of 
view, indications for crystalloid admi-
nistration should be the contraction of 
the extracellular compartment related 
to inappropriate fluid intake, insensi-
ble perspiration, diuresis and surgical 
drainage. (26) When the intravascular 
volume is decreased, it is not logical to 
use crystalloids that mostly extravasate 
into the interstitial compartment. (27) A 
large amount of crystalloids needed for 
the expansion of intravascular compar-
tment could be associated with nume-
rous adverse effects such as pulmonary 
oedema, increased excretory renal fun-
ction, inhibited gastrointestinal motility, 
intestinal mucosa oedema, increased 
intra-abdominal pressure and hyperco-
agulability. (28) According to the “loss-
oriented” fluid management approach, 
izoonotic, balanced and colloid solu-
tions should be used in hypovolemic 
patients because those solutions rema-
in in the circulation and maintain fluid 
homeostasis.(1,2,6) Colloids should 
not be administered in hypervolemic 
conditions. In the “context sensitivity of 
colloidal volume effects” theory, two-
thirds of colloid solutions will be dis-
tributed in the interstitial compartment 
during the hypervolemia. (1,2,9)
The SSCG suggest the use of albumin 
solutions when patients with severe sep-
sis or septic shock require substantial 
amounts of crystalloids. (29) Albumin 
solutions are obtained from pooled 
human plasma and have theoretical 
advantages in comparison to synthetic 
colloids. Nevertheless, the use of albu-
mins did not show convincing results in 
controlled, randomised studies or meta-
analyises. (1) The largest randomised 
study (SAFE) compared the admini-
stration of 4% albumins and 0.9% NaCl 
in 6,997 critically ill patients. (30) The 
results of the study demonstrated similar 
28-day mortality in both groups. A sub-
group analysis of patients with severe 
sepsis showed a benefit trend associa-
ted with the administration of albumins. 
A subgroup analysis of patients with tra-
umatic brain injuries showed increased 
risk of dying in the albumin group. (31) 
The main limitation of the SAFE study 
was that albumin solutions were used as 
a general fluid substitute, not as volume 
replacement therapy. 
The Delaney et al. meta-analysis of 17 
studies and 1,977 patients with severe 
sepsis and septic shock showed that 
treatment with albumins in comparison 
to other solutions reduced mortality. (32) 
The Alderson et al. meta-analysis of 38 
studies and 10,842 critically ill patients 
with hypovolemic shock demonstrated 
no benefit on survival when albumins 
were administered in comparison to 
other solutions. (33) Although studies 
that investigated albumin administrati-
on as volume replacement therapy did 
not show clear benefits, studies in hypo-
albuminemic patients demonstrated 
positive effects of their use concerning 
a fluid balance and haemodynamics, 
better tolerance to enteral feeding and 
improved organ function. (34,35)
Gelatin solutions are produced from 
animal collagen. There are conflicting 
results in literature about the volume 
effectiveness of gelatin solutions. Most 
studies demonstrated lower intravas-
cular volume expansion, increased 
extravasation of infused gelatins and 
less expressed effects on cardiac and 
stroke volume indices in comparison 
to HES solutions. (36,37,38) Although 
kidneys eliminate gelatin solutions very 
rapidly, the effects on kidney function 
are currently unclear. (37) Compared to 
HES solutions, gelatines have reduced 
effects on fibrin polymerisation. (1) An 
impairment of the clot strength after 
cardiac surgery was noticed with both 
colloids. (39) A considerably higher risk 
for anaphylactic reactions is associated 
with the use of gelatin solutions, and 
the transfer of the bovine spongiform 
encephalopathy cannot fundamentally 
be excluded. (40)
Dextrans solutions have major side-
effects that include anaphylactoid 
reactions, renal damage and impaired 
hemostasis. (37) They have lost their 
role in modern volume replacement 
therapy. 
Conclusion
The majority of studies published in 
the past few years have pointed to the 
possibility that in critical illness HES 
solutions are associated with increased 
ARF and RRT and some studies have 
demonstrated a higher mortality rate. 
On the other hand, recent studies and 
analyses suggest that HES solutions 
may be used in hypovolemic critically ill 
patients and in the perioperative setting. 
The use of HES solutions in the future 
will probably depend on revised indi-
cations, doses and the duration of the 
treatment made by regulatory boards 
and manufacturers. Untill then we must 
use them cautiously and in accordance 
with strict therapeutic indications.
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